Randomised, phase II, placebo-controlled, trial of fulvestrant plus vandetanib in postmenopausal women with bone only or bone predominant, hormone-receptor-positive metastatic breast cancer (MBC): The OCOG ZAMBONEY study
Mark J. Clemons, Brandy Cochrane, Gregory R. Pond, Nadia Califaretti, Stephen K.L. Chia, Rebecca Alexandra Dent, Xinni Song, Andre Robidoux, Sameer Parpia, David Warr, Daniel Rayson, Kathleen I. Pritchard, Mark N. Levine
科研成果: 期刊稿件 › 文章 › 同行评审
43
引用
(Scopus)